MYX1715

MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin[1][2].

Product Specifications

CAS Number

[2445448-66-6]

UNSPSC

12352005

Target

ADC Payload; N-myristoyltransferase

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/myx1715.html

Concentration

10mM

Purity

99.55

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(N(C)C)C1=NN(C)C(C)=C1CCOC2=C(C3=CN4C(CCN)=CN=C4C=C3)C=CC(Cl)=C2

Molecular Formula

C25H29ClN6O2

Molecular Weight

480.99

References & Citations

[1]Zhang J, et al. Dysregulation of MYC-Family Proteins Sensitises Cancers to NMT Inhibition: Identification of NMTi Sensitivity and Mechanism[J]. Cancer Research, 2023, 83 (7_Supplement) : 4871-4871.|[2]Carr R, et al. N-Myristoyltransferase (NMT) inhibitors are completely novel payloads for Antibody Drug Conjugates that deliver extensive tumor regression at well tolerated doses[J].